Validity of the 6 minute walk test in facioscapulohumeral muscular dystrophy
dc.contributor.author | Eichinger, Katy | |
dc.contributor.author | Heatwole, Chad | |
dc.contributor.author | Heininger, Susanne | |
dc.contributor.author | Stinson, Nikia | |
dc.contributor.author | Matichak Stock, Carly | |
dc.contributor.author | Grosmann, Carla | |
dc.contributor.author | Wagner, Kathryn R. | |
dc.contributor.author | Tawil, Rabi | |
dc.contributor.author | Statland, Jeffrey M. | |
dc.contributor.author | FSHD Clinical Trials Research Network | |
dc.date | 2022-08-11T08:11:04.000 | |
dc.date.accessioned | 2022-08-23T17:30:42Z | |
dc.date.available | 2022-08-23T17:30:42Z | |
dc.date.issued | 2017-03-01 | |
dc.date.submitted | 2017-04-12 | |
dc.identifier.citation | Muscle Nerve. 2017 Mar;55(3):333-337. doi: 10.1002/mus.25251. Epub 2016 Dec 5. <a href="https://doi.org/10.1002/mus.25251">Link to article on publisher's site</a> | |
dc.identifier.issn | 0148-639X (Linking) | |
dc.identifier.doi | 10.1002/mus.25251 | |
dc.identifier.pmid | 27421252 | |
dc.identifier.uri | http://hdl.handle.net/20.500.14038/50568 | |
dc.description.abstract | INTRODUCTION: In preparation for future clinical trials, we determined the reliability, relationship to measures of disease severity, and consistency across sites of the 6 Minute Walk Test (6MWT) in patients with facioscapulohumeral muscular dystrophy (FSHD). METHODS: Genetically defined and clinically affected FSHD participants at 2 sites performed the 6MWT, the Timed Up and Go, and the 30 foot Go/Timed 10 meter test as measures of mobility using standard procedures. RESULTS: Eight-six participants representing the full range of severity performed the 6MWT. The mean 6MWT distance was 404.3 meters (SD 123.9), with no difference between sites. The 6MWT was reliable (n = 25; intraclass correlation coefficient = 0.99) and demonstrated moderate to strong correlations with lower extremity strength, functional outcomes, and FSHD Clinical Score. CONCLUSIONS: The 6MWT is reliable and is associated with other measures of FSHD disease severity. Future directions include assessing its sensitivity to disease progression. . | |
dc.language.iso | en_US | |
dc.relation | <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=27421252&dopt=Abstract">Link to Article in PubMed</a> | |
dc.relation.url | https://doi.org/10.1002/mus.25251 | |
dc.subject | 6 Minute Walk Test | |
dc.subject | clinical trials | |
dc.subject | facioscapulohumeral muscular dystrophy | |
dc.subject | neuromuscular disease | |
dc.subject | outcome measures | |
dc.subject | Cell Biology | |
dc.subject | Developmental Biology | |
dc.subject | Molecular Biology | |
dc.subject | Molecular Genetics | |
dc.subject | Musculoskeletal Diseases | |
dc.subject | Nervous System Diseases | |
dc.title | Validity of the 6 minute walk test in facioscapulohumeral muscular dystrophy | |
dc.type | Journal Article | |
dc.source.journaltitle | Muscle and nerve | |
dc.source.volume | 55 | |
dc.source.issue | 3 | |
dc.identifier.legacycoverpage | https://escholarship.umassmed.edu/wellstone_pubs/37 | |
dc.identifier.contextkey | 10009687 | |
html.description.abstract | <p>INTRODUCTION: In preparation for future clinical trials, we determined the reliability, relationship to measures of disease severity, and consistency across sites of the 6 Minute Walk Test (6MWT) in patients with facioscapulohumeral muscular dystrophy (FSHD).</p> <p>METHODS: Genetically defined and clinically affected FSHD participants at 2 sites performed the 6MWT, the Timed Up and Go, and the 30 foot Go/Timed 10 meter test as measures of mobility using standard procedures.</p> <p>RESULTS: Eight-six participants representing the full range of severity performed the 6MWT. The mean 6MWT distance was 404.3 meters (SD 123.9), with no difference between sites. The 6MWT was reliable (n = 25; intraclass correlation coefficient = 0.99) and demonstrated moderate to strong correlations with lower extremity strength, functional outcomes, and FSHD Clinical Score.</p> <p>CONCLUSIONS: The 6MWT is reliable and is associated with other measures of FSHD disease severity. Future directions include assessing its sensitivity to disease progression. .</p> | |
dc.identifier.submissionpath | wellstone_pubs/37 | |
dc.contributor.department | Wellstone Center for FSHD | |
dc.source.pages | 333-337 |